Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Alliancebernstein L.P.

Alliancebernstein L.P. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,047,846 shares of the biopharmaceutical company's stock after purchasing an additional 50,434 shares during the quarter. Alliancebernstein L.P. owned about 0.57% of Gilead Sciences worth $651,010,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. C M Bidwell & Associates Ltd. acquired a new position in shares of Gilead Sciences in the fourth quarter valued at about $351,000. Meeder Asset Management Inc. boosted its holdings in shares of Gilead Sciences by 12.9% in the 4th quarter. Meeder Asset Management Inc. now owns 214,606 shares of the biopharmaceutical company's stock valued at $19,823,000 after acquiring an additional 24,571 shares during the last quarter. AIA Group Ltd boosted its stake in shares of Gilead Sciences by 183.4% during the 4th quarter. AIA Group Ltd now owns 14,933 shares of the biopharmaceutical company's stock worth $1,379,000 after acquiring an additional 9,664 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Gilead Sciences by 3.1% in the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after purchasing an additional 1,058,331 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC raised its holdings in Gilead Sciences by 53.1% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 317,302 shares of the biopharmaceutical company's stock worth $29,309,000 after purchasing an additional 110,056 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Remove Ads

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 302,785 shares of company stock valued at $30,503,250 over the last 90 days. Corporate insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of recent analyst reports. BMO Capital Markets boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Oppenheimer upped their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 4th. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Trading Down 1.9 %

Shares of GILD stock traded down $2.14 during mid-day trading on Friday, hitting $110.25. 5,371,465 shares of the company's stock were exchanged, compared to its average volume of 8,576,443. The stock has a 50-day simple moving average of $107.02 and a two-hundred day simple moving average of $95.63. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The stock has a market cap of $137.28 billion, a price-to-earnings ratio of 298.02, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.